-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zerlasiran in Atherosclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zerlasiran in Atherosclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zerlasiran in Atherosclerosis Drug Details: SLN-360 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Beta Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLN-124 in Beta Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLN-124 in Beta Thalassaemia Drug Details: SLN-124 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Alpha Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLN-124 in Alpha Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLN-124 in Alpha Thalassaemia Drug Details: SLN-124 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zerlasiran in Atherosclerosis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Zerlasiran in AtherosclerosisDrug Details:SLN-360 is under development for the treatment of atherosclerotic cardiovascular disease events associated...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Polycythemia Vera
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. SLN-124 in Polycythemia Vera Drug Details: SLN-124 is under development for the treatment of hereditary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-360 in Atherosclerosis
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SLN-360 in Atherosclerosis Drug Details: SLN-360 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Primary (Inherited) Hemochromatosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLN-124 in Primary (Inherited) Hemochromatosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SLN-124 in Primary (Inherited) HemochromatosisDrug Details: SLN-124 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SLN-124 in Alpha Thalassaemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SLN-124 in Alpha Thalassaemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SLN-124 in Alpha ThalassaemiaDrug Details: SLN-124 is under development for the treatment of...
-
Sector Analysis
Green Bites – Key Disruptive Forces in Sustainable Nutrition
Disruptive Forces in Sustainable Nutrition Report Overview Advanced developments such as edible insects, food 3D printing, and plant-based proteins are redefining food efficiency and environmental impact in the sustainable nutrition domain. Innovation Curve: Consumer Buy the Full Report to Know More about the Disruptive Forces in Sustainable Nutrition Download a Free Report Sample The ‘Green Bites – Key Disruptive Forces in Sustainable Nutrition’ FutureTech series report categorizes the key innovation areas in sustainable nutrition as emerging, accelerating, and maturing. The...
-
Company Profile
Fraser & Neave Holdings Bhd – Company Profile
Fraser & Neave Holdings Bhd (F&NHB), a subsidiary of Fraser and Neave Ltd, manufactures and distributes dairy products and beverages. The company's product portfolio comprises isotonic, tea, packaged water, energy drinks, soy drinks, juices, carbonated soft drinks, condensed, evaporated milk, and liquid milk. F&NHB markets products under the 100PLUS, F&N Fun Flavours, Fruit Tree, Borneo, Ranger, est Cola, Gold Coin, Farmhouse, Ice Mountain, Oyoshi, F&N Seasons, F&N NutriSoy, Cap Junjung, Ideal, Tea Pot, Carnation and F&N brand names. It is...
Add to Basket